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RemodelingThe role of hyaluronan in cardiac growth has become evident, previously shown by increased myocardial
levels of hyaluronan in a rat model of cardiac hypertrophy.
To further investigate the role of hyaluronan and regulation of its synthesis in cardiac hypertrophy,
quantitative measurements of myocardial hyaluronan concentration was correlated to gene transcription in
hypertrophic cardiac tissue. Factor analysis was used to study this correlation over time. A subset of
differentially expressed genes was identiﬁed with a transcriptional regulation correlating to the increased
synthesis of hyaluronan, suggesting a common regulatory pathway.
Four transcription factors, Myc, Fos, Junb and Egr1, were also up-regulated. Furthermore, the Ace gene was
up-regulated, representing increase of angiotensin II, an inducer of these transcription factors and fetal
genes in cardiac hypertrophy. This demonstrates a coordinated synthesis of hyaluronan and pro-
hypertrophic gene expression, regulated by immediate early genes, with angiotensin II as a possible
mediator.nd Clinical Medicine/ Medicine,
30760.
Hellman).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
In physiological or pathological cardiac growth, all tissue consti-
tuents, including extracellular matrix (ECM), has to expand in a
coordinated manner in order to maintain optimal function [1]. The
ECM macromolecular structure provides scaffold for myocytes,
ﬁbroblasts, endothelial cells and the vasculature to align [2]. The
main ECM components include structural proteins such as collagens
and elastin, adhesive and anti-adhesive proteins, proteoglycans and
glycosaminoglycans (GAG), as well as interstitial cells like ﬁbroblasts
and macrophages.
Cells have the ability to bind macromolecular ECM components
through transmembrane receptors enabling intracellular signaling
between the ECM and the cell machinery. Thus, the ECM not only
provides structure but is also crucial for cell function and metabolism.
This has been demonstrated in a seminal experiment by reseeding
decellularized hearts with cardiac-derived and endothelial cells,
which respond to the cardiac ECM environment and forms a
functional contracting heart [3].Variation of ECM physico-chemical properties such as elasticity
profoundly affects the maturation of naive mesenchymal stem cells
into different lineages [4,5].
The transcriptional changes during cardiac remodeling have been
studied in several different models using gene expression micro-
arrays. In these studies the patterns of gene expression have been
related to sex, acute and late aortic constriction-induced hypertro-
phies, myocardial infarction, heart chambers, hypertension, different
mutations and stretch vs. pharmacologically stimulated cardiomyo-
cytes [6–15]. Correlations between the gene expression levels and
quantitative measurements of cardiac growth have also been studied
[12,16,17]. All these studies have provided insights into the
underlying genetics of cardiac remodeling and the distinct changes
in the expression of genes coding for ECM proteins.
One ECM component widely distributed is the GAG hyaluronan
(HA), which forms a highly hygroscopic network around cells and
vessels, regulating tissue hydration and osmotic balance. It mediates
intracellular signaling, mainly through the transmembrane receptor
CD44. Apart from these functions it has been shown to be involved in
many processes in the body, includingwound healing, tumour growth
and inﬂammation [18–20]. Animal studies have provided evidence
that HA affects cancer initiation as well as progression and increased
synthesis of HA accelerates tumor growth [21,22]. Absence of HA in
mice heart causes abnormalities in heart and blood vessel
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the importance of HA in the cardiovascular morphogenesis [23].
We have previously described the dynamic regulation of HA over
time in an experimental rat model of cardiac hypertrophy using
abdominal aortic ligation. Thismodel showed increased concentration
of HA in hearts from ligated compared to sham-operated animals [24].
The aim of this study was to investigate the role of HA and the
regulation of its synthesis. Factor analysis was used to study the
correlation between HA concentration and gene expression over time,
to associate HA synthesis with transcriptional pathways in order to
better understand the hypertrophic process. This is the ﬁrst study to
describe the correlation between levels of HA in cardiac tissue with
transcription of growth related genes and signaling pathways.
Materials and methods
Preparation of the animals
A total of 122 male Wistar rats, weighing approximately 200 g,
were included in this study. The animals were anesthetized with
0.2 ml pentobarbital intra-abdominally and after abdominal incision,
a titanium clip of 0.15 mm inner diameter was put around the aorta,
just proximal to the renal arteries. Age-matched control rats were
sham operated and subjected to exactly the same procedure but
without ligating the aorta. The rats were sacriﬁced at 1, 6 and 42 days
postoperatively. To determine if cardiac hypertrophy occurred in the
ligated aorta hearts the heart-to-body weight (HBW) ratio was
calculated. The six hearts with the highest HBW ratio from each
ligated aorta group were used for analysis.
Handling and procedures of laboratory animals were performed
according to the French regulation.
Sample preparation
The hearts were excised after pentobarbital anaesthesia and
immediately washed in NaCl 0.9%, weighed and placed in liquid
nitrogen or RNAlater (Qiagen, Hilden, Germany). For each group, 6
aortic ligated rats and 6 sham operated rats, total RNA was isolated
from heart tissue from the lower part of the left ventricular wall using
the RNeasy Fibrous Tissue Kit (Qiagen, Stanford, CA). RNA concentra-
tion was measured in a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Inc, Wilmington, USA) and the integrity of
the RNA was analyzed in a 2100 Bioanalyser (Agilent Technologies
Inc, Palo Alto, CA).
Quantitative analysis of HA
Thewet weight of the tissue samples from the lower part of the left
ventricular wall was measured before being dried in a rotary vacuum
pump for 3 hours. Dry weights were measured, and then the samples
were homogenised. Sample weight was from 3 to 33 mg of
homogenised tissue. The samples were suspended in a solution of
the protease pronase, 5 Units/ml (Pronase from Streptomyces griseus,
BioChemica, Fluka, Buchs, Switzerland) in tris-buffer (0.05 M Tris–
HCl, 0.01 M CaCl2). Thereafter, 0.1 unit protease per mg tissue was
added to each tissue sample before they were incubated in a water
bath at 55 °C for 16 h. The temperature was then raised to 100 °C, and
samples were boiled for 10 min. 50–100 µl phenylmethanesulfonyl
ﬂuoride (0.1 M in ethanol, BioChemika, Fluka, Buchs, Switzerland)
was added, and samples were centrifuged for 15 minutes at 15000 G.
The supernatant was diluted 20–100 times in PBS and analysed for HA
using an enzyme-linked binding protein assay (Corgenix, Westmin-
ister, USA) according to the manufacturer's instructions. Absorbance
was read at 450 nm with correction at 650 nm on a spectrophotom-
eter (Multiscan Ascent, Thermo Labsystems, Helsinki, Finland).Microarray gene expression
Aliquots of total RNA were converted to biotinylated double-
stranded cRNA according to the speciﬁcations of the Illumina
Totalprep RNA Ampliﬁcation Kit (Ambion, Austin, TX, USA). The
labelled cRNA samples were hybridized to Sentrix RatRef-12 Expres-
sion Beadchip (Illumina, San Diego, CA, USA), incubated with
streptavidin-Cy3 and scanned on the Illumina Beadstation GX
(Illumina, San Diego, CA, USA).
Data analysis
To determine differentially expressed genes microarray data were
analyzed using Illumina Beadstudio software (version 3.3). Intensity
data were normalized using Beadstudios cubic spline algorithm.
Microarray data and information is available through NCBIs Gene
Expression Omnibus (GEO) and are accessible through GEO Series
accession number GSE21600. A number of ﬁltering steps were applied
to avoid false positives. Signiﬁcantdifferential expressionwas calculated
using the Beadstudio software by applying multiple testing corrections
using Benjamini and Hochberg False Discovery Rate (FDR) [25,26]. The
gene expression fold change was calculated as the average signal value
of aorta ligated animals relative to the average signal value of the sham
operated animals. A signiﬁcant up-regulation was deﬁned as a
foldchange ≥1.5 and a signiﬁcant down-regulation was deﬁned as
foldchange ≤0.67. Statistical signiﬁcance was set to Pb0.05. To avoid
selecting genes with high foldchange due to low signal intensity a
minimum signal intensity valuewas utilized. For upregulated genes the
signal intensity was set at N50 in the ligated aorta group, 2.5 times the
highest background signal. For downregulated genes the signal intensity
was set at N50 in the sham group. Linear correlation between HA
concentration in left ventricle and expression levels of signiﬁcantly
differentially expressedgeneswas tested to identify a set of geneswhose
expression changes are associated with changes in HA concentration.
Correlation between HA concentration and gene expression levels were
calculated with SPSS (version 16.0, SPSS Inc., Chicago, Ill, USA). The
Pearson correlation coefﬁcient was used and statistical signiﬁcance was
set to Pb0.05. Factor analysis was performed to examine the change in
correlation over time for the genes with expression levels found to
correlate with HA concentration. Principal components method was
used to analyze correlation matrix and 2 factors were extracted. Since
the differentially expressed genes in growing hearts are regulated
according to a fetal gene program [27], activated by the increased
afterload the sham operated animals could not be included in the
correlation analysis. MetaCore™ (GeneGo Inc. USA) was used to
generate a network between the correlating genes with transcription
factors to elucidate common transcriptional relation between them.
To further increase the knowledge of the environment where HA is
active, genes coding for proteins associated to HA and the ECM were
investigated. Genes coding for proteins such as structural ECM
molecules, cell membrane receptors that bind to ECM structures,
molecules that interact between cell surface and ECM, growth factors
that interact with the ECM and enzymes that regulate the turnover and
remodelingof ECMmoleculeswereﬁltered fromthe lists of signiﬁcantly
differentially expressed genes at the three time points. These genes
were also used to generate a network with transcription factors.
Conﬁrmation of the microarray data with quantitative RT-PCR
Relative quantiﬁcation of mRNA expression of four genes differ-
entially expressed was performed to conﬁrm the validity of the
microarray expression data, using an Applied Biosystems Prism
7900HT Sequence Detection System, according to the manufacturer's
speciﬁcations (Foster City, CA). Omniscript RT Kit (Qiagen, Hilden,
Germany) was used to synthesise cDNA from an aliquot of the
remaining total RNA. Rat cDNA-speciﬁc TaqMan Gene Expression
Table 1
General characteristics and quantiﬁcation of HA in the hearts.
Parameter 1 day 6 days 42 days
Sham A.l. Sham A.l. Sham A.l.
(N=6) (N=6) (N=6) (N=5) (N=6) (N=6)
Heart weight (g) 0.77±0.02 0.89±0.06 0.78±0.12 0.80±0.06 1.15±0.20 1.65±0.08
Body weight (g) 206.7±13.2 210.7±14.4 259.1±11.3 215.2±33.5 403.3±49.2 425.0±39.6
Weight change (g) −8.0±6.6 −24.2±4.5 29.9±20.1 -25.4±24.1 171.5±82.9 250.2±35.4
HBW ratio (mg/100 g) 374.0±18.7 423.2±17.0 298.7±39.1 395.1±36.5 282.6±17.0 391.2±27.2
HA conc. (µg/g d.w.) 141±13 473±262 208±76 251±54 150±34 324±172
P-value 0.037 0.201 0.055
HA conc. (µg/g w.w.) 67±6 178±137 139±56 167±26 65±22 90±54
P-value 0.055 0.234 0.423
Amount of water (%) 52±3 65±15 34±8 32±9 57±9 72±9
P-value 0.332 0.46 0.01
Sham, sham operated animals; A.l., aorta ligated animals; HBW, heart body weight; d.w., dry weight; w.w., wet weight; HA conc., the average HA concentration in the hearts in the
three groups and signiﬁcance of increase in aorta ligated animals compared to sham operated.
75U. Hellman et al. / Genomics 96 (2010) 73–81Assays for Vcan, Itgb1, Ccn2/Ctgf, and Tgfb2 from Applied Biosystems
were used in the study. The rat Gapdh gene was used as an
endogeneous control (part number 4352338E; Applied Biosystems).
All samples were run in triplicates and ampliﬁcation was analyzed
using Applied Biosystems Prism Sequence Detection Software
(version 2.3). Relative quantiﬁcation was calculated according to the
comparative CT method (Applied Biosystems Inc, Foster City, CA)
using a statistical conﬁdence of 99.9%. The amount of target gene
mRNA, normalized to an endogeneous control and relative to a
calibrator, is given by 2−ΔΔCT. [28]. The gene expression fold change of
the animals with ligated aorta is the average 2−ΔΔCT value relative to
the average 2−ΔΔCT value for the sham operated animals. All analyses
on real-time RT-PCR data were performed with SPSS statistical
analysis package (version 16.0, SPSS Inc., Chicago, IL, USA). Differences
between two groups were compared using Mann–Whitney U test and
bivariate correlation was calculated.
Statistical signiﬁcance was set to Pb0.05.
Results
General characteristics
The heart weight increased in the aorta ligated group compared to
the sham group. At day 1 after operation, the heart weight of the aorta
ligated animals was 15% higher than the sham operated group. At day
42 the weight had increased by 43% (Table 1). The operation initiallyTable 2
Differentially expressed genes associated with cardiac hypertrophy, in rats at three time
points after aortic ligation.
1 day 6 days 42 days
Foldchange P-value Foldchange P-value Foldchange P-value
Nppa 2.6 0.031 7.4 0.0007 7.0 0.044
Nppb 1.39 0.24 1.7 0.10 2.4 0,019
Acta1 1.6 0.073 1.9 0.19 2.5 b0.00001
Myh6* 0.6 0.010 1.1 0.34 0.9 0.33
Myh7* 3.9 0.004 2.4 0.054 3.0 0.045
Egr1 2.1 0.032 2.0 1.0 2.0 0.0016
Myc 4.0 0.0012 3.0 1.0 1.2 1.0
Fos 4.1 0.0017 1.9 1.0 0.4 1.0
Junb 2.6 0.014 3.9 0.75 1.4 0.29
Ace 3,1 0,002 4,6 0,187 0,7 0,793
Ace2 1,2 1,000 0,6 1,000 1,9 0,002
Nppa, Natriuretic peptide precursor type A; Nppb, Natriuretic peptide precursor type B;
Acta1, skeletal actin alpha 1; Myh6, myosin heavy chain, cardiac muscle, alpha; Myh7,
myosin heavy chain, cardiac muscle, beta; Egr1, Early growth response 1; Myc,
myelocytomatosis viral oncogene homolog; Fos, FBJ murine osteosarcoma viral
oncogene homolog; Junb, jun B proto-oncogene; Ace and Ace2, angiotensin-
converting enzyme 1 and 2. *Myh6 and Myh7 analysed with real-time PCR in earlier
study.caused all rats, in particular the aorta ligated group, to lose weight
which affected the HBW calculations. Genes traditionally used as
markers for cardiac hypertrophic growth and the fetal gene program
(Nppa, Nppb, Acta1, Myh6 and Myh7) showed an increased expression
as early as 1 day after surgery in the aorta ligated rat hearts. As
expected changes in early genes was observed only at the acute phase
(Table 2).
Quantiﬁcation of HA
The average HA concentration in the hearts of the sham operated
animals correlated well to earlier studies [29]. The average HA
concentration in the hearts at day 1 was increased threefold [30] in
the aorta ligated animals and the concentration was signiﬁcantly
increased compared to sham operated animals (P=0.037). The
concentration at day 6 was not signiﬁcantly increased compared to
sham operated animals (Table 1).
Microarray gene expression
The microarray data was ﬁltered by controlling FDR, setting
statistical signiﬁcance to Pb0.05, foldchange to ≥1.5 and ≤0.67 and
minimum signal intensity to ≥50. The number of genes that were
signiﬁcantly up- or down-regulated on the chip at day 1, 6 and 42 wasFig. 1. Number of differentially expressed genes after different ﬁltering steps. Statistical
signiﬁcance was set to Pb0.05. Multiple testing corrections using False Discovery Rate
(FDR) was applied. A signiﬁcant up-regulation was deﬁned as a foldchange ≥1.5 and a
signiﬁcant down-regulation was deﬁned as foldchange ≤0.67. A minimum signal
intensity value of 50 was utilized. Linear correlation between HA concentration and
expression levels of differentially expressed genes was tested. Avg. sign., average signal.
Corr., correlates. Conc., concentration.
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106 (14%), 4 (2%) and 31 (8%) that correlated with the concentration
of HA in the left ventricle in the hearts. Of the 106 genes, 81 were
identiﬁed and have a known function. The MetaCore™ (GeneGo Inc.
USA) bioinformatics software was used to generate a network
between the correlating genes with transcription factors (Fig. 2).
The three networks with the best P-values and centered on
transcription factors expressed in the rat hearts were merged into
one network, including other signiﬁcantly differentially expressed
transcription factors at day 1. This revealed an enrichment of genes
regulated by 5 transcription factors, tumour protein p53 (Tp53),
speciﬁcity protein 1 (Sp1), myelocytomatosis viral oncogene homolog
(Myc), FBJ murine osteosarcoma viral oncogene homolog (Fos) and
jun B proto-oncogene (Junb). Fos, Junb and Myc were up-regulated at
day 1 (Table 2), the ﬁrst two are likely to form a complex, activator
protein-1 (AP-1).Fig. 2. Network generated by the MetaCore™ (GeneGo Inc. USA) bioinformatics software.
transcription factors. The expression of transcription factors do not correlate to HA concentra
and red circles up-regulation. Green arrows indicate activation and red arrows inhibition
binding protein; transcription factor; GTPase; G-protein adaptor; receptor; receptGenes with association to HA speciﬁcally and the ECM in general
were ﬁltered from the lists of signiﬁcantly differentially expressed
genes at the three time points (Table 3). These 37 genes were also
used to generate a network with transcription factors. Most of the
genes were also bioinformatically found to be transcriptionally
regulated by TP53, SP1, AP-1 and MYC (Fig. 3). Four of these genes,
CD44, Biglycan (Bgn), Latent transforming growth factor beta binding
protein (Ltbp2) and ﬁbrillin1 (Fbn1), correlated signiﬁcantly with HA
concentration levels.
The change in correlation with HA concentration over time with
the 106 genes at day 1 and the 31 genes at day 42, were analyzed with
factor analysis and illustrated with component plots in rotated space
(Fig. 4a and b). The 106 genes from day 1 formed two tight clusters,
positive correlation to HA concentration in the upper right corner and
negative correlation in the lower left corner. The same genes in
animals from day 6 showed clustering but less tight. At day 42 theThe differentially expressed genes correlating with HA concentration are centered on
tion but Egr1, Fos, Junb andMyc are up-regulated. Blue circles indicate down-regulation
. The symbols are as follows: enzyme; kinase; protease; protein; generic
or ligand; channel.
Table 3
ECM related gene expression of aorta ligated vs. sham-operated animals.
Gene 1 day 6 days 42 days
Structural ECM genes
Vcan ↑ = =
Cspg4 (↑) (↑) ↑
Cspg5 = ↓ =
Fbn1 ↑ ↑ =
Fbn2 ↑ = =
Fbln1 ↓ = =
Fbln2 = ↑ (↑)
Fn1 (↑) ↑ =
Selp ↑ = =
Lamc1 ↑ = =
Lama5 (↑) ↑ =
Col6a3 ↑ = =
Col8a1 ↑ (↑) ↑
Col15a1 ↓ = =
Col16a1 ↑ (↑) =
Col18a1 ↑ ↑ =
Bgn ↑ (↑) ↑
ECM associated genes
Itgb1 ↑ ↑ =
Itga5 ↑ = =
CD38 ↓ = ↓
CD44* ↑ ↑ =
Ccn1/Cyr61 ↑ = =
Ccn2/Ctgf ↑ ↑ (↑)
Ccn3/Nov ↓ ↑ =
Ccn5/Wisp2 (↑) (↑) =
Tgfb1 (↑) = =
Tgfb2 ↑ ↑ ↑
Ltbp1 ↓ = (↓)
Ltbp2 ↑ ↑ ↑
Thbs4 (↑) (↑) ↑
Timp1 ↑ (↑) ↑
Timp2 ↓ = (↓)
Mmp23 ↑ ↑ =
Ctsc ↓ = (↓)
Ctsk (↑) ↑ =
Adamts1 ↑ = =
Adamts5 = = ↓
Ugdh ↑ = =
Vcan, versican; Cspg, chondroitin sulphate proteoglycan; Fbn, Fibrillin; Fbln, Fibulin;
Fn1, Fibronectin1; Selp, P-selectin; Lamc1, Laminin c1; Lama5, Laminin a5; Col,
Collagen; Bgn, Biglycan; Itgb1, Integrin beta1; Itga5, Integrin alpha5; Ctgf, Connective
tissue growth factor; Cyr, Cysteine rich protein; Nov, Nephroblastoma overexpressed;
Wisp, Wnt-induced secreted proteins; Tgfb, Transforming growth factor beta; Ltbp,
Latent transforming growth factor beta binding protein; Thbs, Thrombospondin; Timp,
Tissue inhibitor of metalloproteinase; Mmp, Matrix metallopeptidase; Ctsc, Cathepsin
C; Ctsk, Cathepsin K; Adamts, A disintegrin-like and metallopeptidase with
thrombospondin type 1 motif; Ugdh, UDP-glucose dehydrogenase.
↑ and ↓ indicates change in expression in aorta ligated animals compared to sham
operated. = indicates no signiﬁcant change. Arrows in brackets indicate non-signiﬁcant
changes with a P-value between 0.05 and 0.3. *CD44 analysed with real-time PCR in
earlier study.
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day 42 showed an inverse development over time. Day 42 a tight
correlation was evident but at days 1 and 6 no cluster was seen. In the
sham animals no cluster of correlating genes were observed.
Quantitative RT-PCR
The levels of Vcan, Itgb1, Ccn2/Ctgf, and Tgfb2 mRNA were
measured with real-time PCR and in all cases the foldchange was
greater than with the Illumina microarray beadchip (Supplemental
Table 2). The P-values showed higher signiﬁcance in all cases except
Ccn2, where the P-value was slightly higher but still signiﬁcant.
Differences between the twomethods can be explained by the several
more steps of handling the RNA before hybridizing it to the chip
compared to the single RT-PCR step before the real-time PCR. This is
likely to cause more sample variation in the microarray analysis andtherefore higher P-values compared to using real-time PCR. Correla-
tion between the results was signiﬁcant expect in the case of Itgb1.
Despite some differences between real-time PCR and microarray the
results conﬁrm the expression patterns seen on the microarrays.
Discussion
Up-regulation of HA synthases and an increased HA concentration
as well as up-regulation of CD44 occurs, have previously been shown
in growing hearts of aorta ligated rats [24]. To further investigate the
changes in HA synthesis in this animal model, correlation between
HA synthesis and gene expression changes was investigated.
Correlation between gene expression levels and quantitative mea-
surements of cardiac growth has been proposed to be more
informative than traditional comparison between two conditions.
By using this method it was possible to associate an increased
synthesis of HA to an activation of the fetal gene program in the
heart, indicating a possible mechanism for the involvement of HA in
the cardiac growth process.
A stepwise bioinformatic approach was used to analyse gene
expression data. After ﬁltering the differentially expressed genes by
applying FDR, limiting foldchange and signal levels, the expression
levels of the remaining genes were ascertained for correlation with
HA concentration in the hearts.
Subsets of the differentially expressed genes that correlated with
HA concentrations at day 1, 6 and 42 were identiﬁed. Thus, HA
synthesis and such genes are likely to be governed by a common
regulatory pathway.
With factor analysis it was possible to demonstrate that genes,
which expression levels correlated with HA concentration at day 1 in
aorta ligated animals, also correlated in a similar way after 6 days. It is
important to point out that using the same strategy, no correlation
was found between these genes in the sham operated animals at any
time point. This makes it less likely that the observed changes seen in
gene expression are caused by stress due to operation trauma.
One explanation to the temporal differences seen in gene
correlation could be the expression of different HA synthases.
Previous studies in the same rat model, showed both Has1 and 2
up-regulation at day 1 and 6 [24]. Has2 returned to control levels at
day 42 while Has1 was still up-regulated. This indicates that HA
derived from HAS1 is synthesized for a different purpose in the late
phase of the hypertrophic development of the heart and therefore
regulated by other factors.
The renin angiotensin system (RAS) is a known regulator of
cardiac growth. Angiotensin II (Ang II) is a prohypertrophic effector
peptide, while angiotensin 1-7 has the opposite effect, activated by
angiotensin-converting enzyme ACE and ACE2, respectively [31,32].
These corresponding genes also showed distinct temporal patterns of
expression with acute up-regulation of Ace at day 1 and a late
response of Ace2 at day 42 (Table 2). Most likely the observed co-
regulation of genes with HA concentrations at day 1 and 6 reﬂects the
acute hypertrophic process while the genes being active at day 42
shows a shift to a steady state program mirrored by the expression
levels seen in Has1 and Has2 as well as Ace and Ace2.
To test the hypothesis that there is a common signaling pathway,
regulated by the same transcription factors, the bioinformatic
software MetaCore™ (GeneGo Inc. USA) was used. The differentially
expressed genes correlating with HA concentration at day 1 as well as
genes with association to HA speciﬁcally and the ECM in general, were
investigated. This analysis revealed an enrichment of genes regulated
by 6 transcription factors, JUNB, FOS, MYC, TP53, SP1 and EGR1, the
former two possibly assembling AP-1 complexes [33–36] (Figs. 2
and 3). Four of these transcription factors, Junb, Fos, Myc and Egr1
were up-regulated at day 1, indicating strong association to the
transcriptional changes in the aorta ligated animals. Junb, Fos,Myc and
Egr1 are immediate early genes (IEG), activated in response to stimuli
Fig. 3. Network generated by the MetaCore™ (GeneGo Inc. USA) bioinformatics software. Genes coding for proteins such as structural ECMmolecules, cell membrane receptors that
bind to ECM structures, molecules that interact between cell surface and ECM, growth factors that interact with the ECM and enzymes that regulate the turnover and remodeling of
ECM molecules were ﬁltered from the lists of signiﬁcantly differentially expressed genes at all three time points. Gene and protein network was generated by the MetaCore™
(GeneGo Inc. USA) bioinformatics software. Green arrows indicate activation and red arrows inhibition. The symbols are as follows: enzyme; kinase; protease; protein;
generic binding protein; transcription factor; GTPase; G-protein adaptor; receptor; receptor ligand.
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known as early regulators of cell growth and to precede the
expression of cardiac hypertrophy markers, e.g. skeletal α-actin and
ANP. The correlation of HA synthesis to the expression of ANP, which
is regulated by the ACE and IEGs, opens the possibility that HA also is
part of the fetal gene program activated in cardiac hypertrophy.
A hallmark of cardiac hypertrophy is ECM remodeling. The
extensive involvement of the ECM in cardiac hypertrophy, including
the increased HA synthesis, is illustrated by the structural ECM genes
with changed expression shown in Table 3a. HA binds directly to
collagen VI α3 and VCAN [41]. The proteoglycan VCAN forms huge
aggregates with HA, around which an extensive matrix is organised
[42,43]. Both HA and VCAN levels have been correlated to progression
of tumor growth [21,22,44,45]. Fibronectin1 (FN1) and FBN1 also bind
to VCAN and the expression of Fbn1 correlated with HA concentration.
Expression of Bgn, another proteoglycan, also correlated with HA
concentration. BGN binds to FN1, collagen VI and TGFB. TGFB is a
positive regulator of Bgn and TGFB/BGN have been proposed to have a
role in pathological remodeling of the heart [46]. Furthermore two
ECM receptors, associated to tissue and tumour growth, CD44 and
integrin α5β1 (Itga5/Itgb1), were both up-regulated. The main
receptor of HA, CD44, correlated to HA concentration, indicating a
close co-regulation. The up-regulated Itga5/Itgb1, the isoform being
more common in the fetal heart, suggests that the myocardium is
expressing receptors capable of recognizing an ECM similar to that of
a fetal heart. Integrins transmit mechanical force across the cell
membrane, triggering intracellular signaling pathways including thehypertrophic gene program [47,48]. ITGA5/ITGB1 is also a receptor
for VCAN, FN and CCN2/CTGF. Recently it was shown that CCN2/CTGF
induces cardiac hypertrophy and is up-regulated during myocardial
ischemia [49,50]. One of themost potent inducers of Ccn2/Ctgf is TGFB
and the involvement of TGFB in cardiac hypertrophy and angiogenesis
is well recognized [51,52]. CCN2/CTGF can also bind directly to TGFB
and FN. Interestingly, both TGFB1 and TGFB2 induce synthesis of HA
and expression of VCAN [53,54]. TGFB is secreted and stored in the
ECM as a complex between a latent TGFB dimer and LTBP, which
binds to both FBN and FN. The up-regulation of Tgfb2 and Ltbp2
together with Fbn1 and Fn1 in this model suggests an ECM serving as a
repository for TGFB as a part of the induced hypertrophic remodeling.
Both Ltbp2 and Fbn1 expression levels correlated to HA concentration.
The physical proximity of these ECM proteins and receptors to HA and
correlation to HA synthesis reveals a collective change in response to
aortic ligation and cardiac hypertrophy.
Assuming that cells need a certain ECM composition for growth,
the observed changes in transcription may represent a demand for a
remodeling of the ECM. Subsequently when cell receptors respond to
the remodeled ECM, the growth can progress. This is in accordance
with a recently published review by Richard Hynes who postulated
that the ECM, together with growth factors, play “chords” on several
receptors simultaneously to transduce intracellular signaling [55]. An
example of ECM inﬂuence over cells, is the reseeding of decellularized
hearts with cardiac-derived and endothelial cells, where the cells
respond to the cardiac ECM environment and form a functional
contracting heart [3].
Fig. 4. (a) Factor analysis of genes correlation with HA concentration at day 1. There were 742 differentially expressed genes at day 1 in aorta banded animals, of which mRNA levels
of 106 genes correlated with the concentration of HA. Factor analysis was performed to examine the change in correlation over time between these 106 genes, illustrated by
component plots. The plots show positive correlation to HA concentration to the left side and negative correlation on the right side of the plot. Clustering of genes in the plot indicate
that they have similar expression regulation. The 106 genes formed two tight clusters on day 1. The same genes also showed clustering at day 6 but less tight. At day 42 the
correlation between the genes was lost. No correlation was found between these genes in the sham operated animals at any time point. (b) Factor analysis of genes correlation with
HA concentration at day 42. There were 371 differentially expressed genes at day 42 in aorta banded animals, of which mRNA levels of 31 genes correlated with the concentration of
HA, forming a tight cluster in the component plot (top right). At days 1 and 6 no cluster was seen, norwas any correlation found between these genes in the sham operated animals at
any time point.
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80 U. Hellman et al. / Genomics 96 (2010) 73–81A limitation of this study is that the cardiac hypertrophy induced
by aortic ligation is an extreme procedure and causes acute responses
that are hardly found in human diseases like aortic stenosis and
hypertrophic cardiomyopathy. However, the controlled timing of the
cardiac growth and high inﬂuence on gene transcription makes it a
suitable model, where relatively few animals are needed for cardiac
growth studies.
In conclusion we found a co-variation between HA and speciﬁc
genes indicating a common regulatory pathway and transcription
factor(s). The importance of HA in cardiac remodeling is also reﬂected
by the differential expression of several genes coding both for
structural and regulatory molecules interacting within the ECM and
the expression of immediate early transcription factors. These
transcription factors, MYC, FOS, JUNB and EGR1, are known to
regulate several of the genes that correlated to the HA concentration,
indicating the involvement of immediate early genes in the synthesis
of HA. The up-regulation of the Ace gene induces the expression of
these transcription factors and also the re-expression of fetal genes
(e.g. skeletal α-actin and ANP) in cardiac hypertrophy. The coordi-
nated synthesis of HA and expression of pro-hypertrophic genes,
regulated by immediate early genes, suggests that HA is a part of the
fetal gene program.
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